2023-508497-28-00招募中2 期
A Phase 2, randomised, open label, multicentre study of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 65
- 试验地点
- 8
- 主要终点
- PFS defined as time from randomisation until the date of first progression or death, whichever occurs first. PFS will be assessed using computed tomography (CT) or magnetic resonance imaging (MRI) and according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
研究概览
简要总结
To compare progression free survival (PFS) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer with peritoneal metastasis that are homologous recombination (HR) proficient following Radspherin® treatment versus no treatment.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Able and willing to provide written informed consent and to comply with the clinical study protocol (CSP).
- •Confirmed HR proficient tumour.
- •Received NACT (numbers of cycles as per investigator’s discretion) with regress or stable disease on diagnostic imaging and assessed to be operable to R0 pre-surgery.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 to 2 and patient fit enough to undergo IDS and further treatment according to standard of care.
- •Adequate renal function: Calculated creatinine clearance using the Cockcroft-Gault formula ≥ 40 ml/min or measured creatinine clearance ≥ 40 ml/min.
- •Adequate hepatic function: 1) Serum bilirubin < 1.5 x upper limit of normal (ULN), and 2) Aspartate transaminase and alanine transaminase ≤ 3 x ULN.
- •Adequate bone marrow function: 1) Absolute neutrophil count ≥ 1.0 x 10^9/l, and 2) Platelets ≥ 100 x 10^9/l, and 3) Haemoglobin ≥ 9 g/dL.
- •For females of childbearing potential, a negative pregnancy test must be documented prior to enrolment.
- •For females of childbearing potential agreement to use at least one of the following highly effective (failure rate < 1%) methods of contraception during the treatment period and for at least 9 months if they receive Radspherin®, unless hysterectomy or oophorectomy is performed during IDS. 1) Total abstinence (when this is in line with the preferred and usual lifestyle of the patient), periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 2) Female sterilisation (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before enrolment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment. 3) Use of oral (oestrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Note: In addition to the use of one highly effective method of contraception as listed above, a condom is required for all male partners during the treatment period and for at least 9 months after the dose of IMP, unless vasectomised at least 6 months prior to enrolment.
- •Female of age ≥ 18 years.
- •Patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO Stage IIIB/C or IV).
- •Peritoneal and other metastases eligible for IDS to no residual tumour.
- •Adverse events recovered to at least Grade 1 from the effects (excluding alopecia) of any prior medical therapy for malignancy.
排除标准
- •Known somatic or germline BRCA1 or BRCA2 mutations or confirmed HR deficient.
- •Active liver disease with positive serology for active hepatitis B, hepatitis C or known human immunodeficiency virus (HIV).
- •Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease.
- •Any condition or illness that, in the opinion of the investigator or the medical monitor, would compromise the safety of the patients or interfere with the evaluation of the safety of the investigational medicinal product.
- •In the investigator’s opinion not able to comply with study procedures. Any medical or psychological condition that would preclude participation in the study or compromise the ability to give informed consent.
- •Administration of an investigational medicinal product within 4 weeks, or at least 5 times the half-life, prior to enrolment.
- •Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to, and up to 4 weeks after the surgery.
- •Treatment with bevacizumab within 5 weeks prior to IDS.
- •Known hypersensitivity to any of the excipients of the study drug.
- •Suspicion of peritoneal leak, shunt, or otherwise suspected atypical target compartment pharmacokinetics, based on investigator’s judgement, patient history and diagnostic images.
- •Epithelial borderline tumours, ovarian clear cell carcinoma, mucinous ovarian carcinoma, malignant Brenner tumours, non-epithelial ovarian malignancies, carcinosarcoma and neuroendocrine tumours or recurrent ovarian cancer.
- •Symptomatic central nervous system metastasis.
- •Another primary malignancy within the past 3 years (except for non-melanoma skin cancer, cutaneous melanoma stage 1, cervical cancer in situ or FIGO 2023 Stage IA1 or IA3 prior or synchronous endometrial cancer).
- •Prior abdominal/pelvic radiotherapy.
- •Disease progression during NACT.
- •Pregnant or lactating (nursing) women.
- •Active infections requiring antibiotics, and/or physician monitoring, or recurrent fever > 38.0 ⁰C associated with a clinical diagnosis of active infection.
结局指标
主要结局
PFS defined as time from randomisation until the date of first progression or death, whichever occurs first. PFS will be assessed using computed tomography (CT) or magnetic resonance imaging (MRI) and according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
PFS defined as time from randomisation until the date of first progression or death, whichever occurs first. PFS will be assessed using computed tomography (CT) or magnetic resonance imaging (MRI) and according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
次要结局
- OS defined as time from date of randomisation until the date of death from any cause.
- PPFS defined as the date from randomisation until the date of first progression in the peritoneum or death for any cause, whichever occurs first. PPFS will be assessed using CT/MRI and according to RECIST v1.1.
- TFST defined as the time from the date of randomisation until the date of first subsequent anticancer therapy or death from any cause, whichever occurs first. Planned post-operative chemotherapy and planned maintenance therapy is considered as a part of the primary treatment and should not be assessed as new subsequent anticancer therapy.
- TSST defined as the time from the date of randomisation to the date of second subsequent anticancer therapy or death from any cause, whichever occurs first. Planned post-operative chemotherapy and planned maintenance therapy is considered as a part of the primary treatment and should not be assessed as new subsequent anticancer therapy.
- Change in biomarker (CA125).
- Changes from baseline in patient reported outcome scores using QoL forms European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ- OV28.
研究者
Information Desk
Scientific
Oncoinvent Solutions AS
研究点 (8)
Loading locations...
相似试验
招募中
3 期
A Study of Duvelisib Versus the Anti-cancer Drugs Gemcitabine or Bendamustine in Patients With T Cell lymphoma (a type of blood cancer), which originated from a certain type of T cells Called T Follicular Helper (TFH) cells (Nodal T Cell Lymphoma with T Follicular Helper [TFH] phenotype), that has returned (relapsed) or that is resistant to other treatments (refractory)2024-516605-23-00Secura Bio Limited78
招募中
4 期
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed on platinum-based chemotherapy2022-501606-35-01Immunogen Biopharma (Ireland) Limited, Immunogen Inc.110
进行中（未招募）
3 期
A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT in patients with mHSPC (ARASAFE)prostate cancer2022-502634-52-00Friedrich-Schiller-Universitaet Jena280
招募中
2 期
PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER (THE CADILLAC STUDY)2024-520027-88-00Medica Scientia Innovation Research S.L., Medica Scientia Innovation Research S.L.27
已完成
2 期
A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to test the effect of brigatinib after standard chemotherapy and radiation therapy is completed.2022-502467-38-00ETOP IBCSG Partners Foundation41